All residents of 3 villages in Ballabgarh (n = 16,861) in Haryana, India, have been under weekly household surveillance for febrile ARI since November 2009 as part of a clinical trial of seasonal inactivated trivalent influenza vaccine in children 6 months–10 years of age (NCT00934245;
www.clinicaltrials.gov); 95% of eligible children were recruited for this trial (). Information on febrile ARI, which consists of reported fever plus any respiratory complaint (e.g., cough, sore throat, nasal congestion, runny nose, earache, or difficulty breathing), was collected for all household members either by self-report or by proxy by trained field workers. Consent was obtained from all participants.
| Table 1Demographic data for persons under surveillance and incidence of febrile ARI and influenza A(H1N1)pdm09 during pandemic and postpandemic periods, Ballabgarh, India* |
During November 2009–October 2010, of the 12,896 eligible persons with febrile ARI, samples were collected from 10,002 (78%); missing samples were because those persons were not available for testing at the time of home visit. Throat and nasal swab specimens were collected from all available febrile ARI patients and tested by using real-time reverse transcription PCR (
10). Incidence rates (IRs; reported as per 1,000 person-years) and corresponding 95% CIs were calculated for the peak periods of influenza circulation. The pandemic period was defined as November 2009–January 2010 and the postpandemic period as August–October 2010 (first postpandemic period). The Institutional Review Boards of All India Institute of Medical Sciences, University of Alabama, and Centers for Disease Control and Prevention approved the study. Informed consent was obtained for all persons included in the study.
Two distinct peaks of pH1N1 activity were identified during the pandemic and postpandemic periods (), with some circulation during the intervening period (February–July 2010, <0.6%). Rates of positive test results for pH1N1 were higher during peak pandemic (21%) compared with peak postpandemic (13%) periods, whereas influenza B positivity was higher during the postpandemic period (). The median age of persons with pH1N1 illness during the postpandemic period was significantly higher than during the pandemic period (18 vs. 9 years of age; p<0.001).
IRs for pH1N1 were higher for children 0–5 and 6–18 years of age (IR 375 and 331, respectively) than for adults (IR 8–86) during the pandemic period (). The differences in IRs of pH1N1 across age groups disappeared during the postpandemic period, however, this occurred primarily because of a decrease in IRs among the 0- to 5- and 6- to 18-year-old age groups (incidence rate ratio [IRR] 0.6) and concurrent increases among older age groups (IRR 1.6–8.7). These changes were statistically significant (p<0.0001; , panel A). The overall IR for influenza B was higher during the postpandemic period; IR for influenza B remained higher for children <18 years of age regardless of pandemic period (, panel B).
| Table 2Incidence rates for influenza A(H1N1)pdm09 and influenza B among persons with febrile ARI during pandemic and postpandemic periods, by age group, Ballabgarh, India* |
The overall IR for pH1N1 was higher for children <18 years of age (345) than for adults >18 years of age (69) during the pandemic period, whereas IRs were similar among children (199) and adults (131) during the postpandemic period. However, the IR of pH1N1 was significantly higher (p<0.0001) among children during the pandemic period compared with the postpandemic period (IRR 0.6), whereas the rate for adults was higher during the postpandemic period (IRR 1.8) (, insets). In contrast, the IR for influenza B remained 2.5× higher for children (IR 184) than adults (IR 72) during the postpandemic period.